Cerebral Small Vessel Disease in Patients with Immune-Mediated TTP

Overview

This study investigates the prevalence of cerebral small vessel disease (cSVD) in patients with immune-mediated thrombotic thrombocytopenic purpura (iTTP) during acute episodes and remission phases. MRI findings reveal significant microvascular injury associated with iTTP, highlighting the need for ongoing neurological assessment.

Background

Thrombotic thrombocytopenic purpura (TTP) is a rare but life-threatening condition characterized by severe deficiency of ADAMTS13, leading to thrombotic microangiopathy. Neurological complications are common in iTTP, with approximately 60% of cases experiencing symptoms such as ischemic stroke and cognitive impairment. Understanding the relationship between iTTP and cSVD is crucial for managing long-term neurological outcomes in affected patients.

Data Highlights

No numerical data or trial data provided in the source material.

Key Findings

• cSVD is prevalent among patients with acute iTTP, contributing to neurological impairment.
• Approximately 60% of iTTP cases involve neurological symptoms due to microthrombotic ischemia.
• MRI findings indicative of cSVD include white matter hyperintensities, lacunes, and cerebral microbleeds.
• Each increment in total cSVD score correlates with increased risk of subsequent stroke and dementia.
• Long-term survivors of iTTP show a higher burden of cerebrovascular injury compared to age- and sex-matched controls.

Clinical Implications

Healthcare professionals should monitor neurological status in iTTP patients, particularly for signs of cSVD. MRI assessments may be warranted during acute episodes and follow-up to evaluate microvascular injury and guide management.

Conclusion

The study underscores the significant prevalence of cSVD in iTTP patients, necessitating careful neurological evaluation and management strategies to address potential long-term complications.

Related Resources & Content

1. 2025 Focused Update of the 2020 ISTH Guidelines for Management of Thrombotic Thrombocytopenic Purpura - PMC
2. Silent cerebral infarction during immune TTP remission: prevalence, predictors, and impact on cognition | Blood | American Society of Hematology
3. Frontiers in Neurology — Associations of intracranial arterial stenosis and cerebral small vessel diseases with acute ischemic lesions in spontaneous intracerebral hemorrhage
4. Frontiers in Neurology — Impact of cerebral small vessel disease burden and systemic clinical phenotypes on short-term neurological outcomes after acute ischemic stroke
5. Frontiers in Immunology — The Interplay between Neuroinflammation and Endothelial Dysfunction in Cerebral Small Vessel Disease
6. Annals of Neurology — Hyperacute Interleukin-1β Production and Neutrophil Extracellular Trap Formation in the Cerebral Circulation of Stroke Patients with Large Vessel Occlusion
7. 2025 Focused Update of the 2020 ISTH Guidelines for Management of Thrombotic Thrombocytopenic Purpura - PMC
8. Silent cerebral infarction during immune TTP remission: prevalence, predictors, and impact on cognition | Blood | American Society of Hematology
9. Reduced ADAMTS13 activity during TTP remission is associated with stroke in TTP survivors - PMC